WUXI TIDES
LIVE

Serial Number

97775103

Owner

Shanghai SynTheAll Pharmaceutical Co., Ltd.

Attorney

Jonathan M. Rixen

First Use Date

Mar 29, 2023

Filing Date

Jan 31, 2023

Add to watchlist:

No watchlists yet
View on USPTO

WUXI TIDES Trademark

Serial Number: 97775103 • Registration: 7961204

WUXI TIDES is a trademark filed by Shanghai SynTheAll Pharmaceutical Co., Ltd. on January 31, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Shanghai SynTheAll Pharmaceutical Co., Ltd. (11 trademarks)

NO.9 Yuegong Road,

Entity Type: 99

Trademark Details

Filing Date

January 31, 2023

Registration Date

September 23, 2025

First Use Anywhere

March 29, 2023

First Use in Commerce

April 17, 2023

Published for Opposition

March 12, 2024

Goods & Services

Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cancer, autoimmune disease, coagulation disorder, infectious disease; Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Raw material medicine, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases; Pharmaceutical preparations, for the treatment of cancers, inflammatory diseases, autoimmune diseases, infectious diseases, and coagulation disorders; pharmaceutical preparations, namely, antivirals; Chemico-pharmaceutical preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases; Biological preparations for medical purposes for the treatment of cancer; Chemical preparations for the diagnosis of pregnancy; Chemical preparations for pharmaceutical or medical purposes, namely, for cancers, inflammatory diseases, autoimmune diseases, infectious diseases, and coagulation disorders healthcare and clinical applications; Chemical preparations for medical purposes, namely, chemical reagents for medical purposes; Chemical preparations for medical purposes for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases; Diagnostic preparations for medical purposes; Nutritional supplements; Drugs for medical purposes for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases; Reagent paper for medical purposes; Medical reagent; Disinfectants for hygiene purposes; Cultures of microorganisms for medical use; Biomedicines for the treatment of cancer, cardiovascular, hematologic, neurological,; gastrointestinal and genetic diseases; Adjuvants for medical purposes; Vaccines; Veterinary preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases

Computer programming; Material testing; Technical research in the field of pharmaceutical studies; Research and development of new products for others; Technology consultancy in the field of cybersecurity; Chemical analysis; Chemistry services, namely, chemistry consultation; Chemical research; Biological research; conducting clinical trials for others, being for scientific and medical research; Quality checking and testing, namely, quality control for others; Scientific laboratory services; Genome structure and function analysis; Gene screening, namely, DNA screening for scientific research purpose; Biomedical research services; Stem cell research service; Drug research and development services, namely, pharmaceutical research; cell culture services for scientific research purposes, for others; Design and development of computer hardware and software; Development and creation of computer programs for data processing; Computer programming in the field of medical treatment; Product quality testing; assessment of quality of products; Scientific research; Surveying; Bacteriological research; The design, production in the nature of design, or maintenance of a computer program; Computer software design; Computer technology consultancy in the field of engineering; Information technology consulting relating to computer network design; Artificial intelligence technology consulting; Research on artificial intelligence technology; Research and development of new products; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Drug evaluation, namely, pharmaceutical product evaluation; Vaccine research and development services; Cancer medicine research; Biotechnology research; Drug testing being testing of pharmaceuticals; Pharmaceutical research; Cancer scientific research for medical purposes; Development and Test of Chemical production methods; Implementing of early evaluation in the field of new drugs, namely, product quality testing; Biochemical research and analysis; Chemical analysis evaluation service; Chemical synthesis evaluation service; scientific research of the mode of action of chemical combinations on animals

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 23, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 23, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 3, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 29, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Aug 8, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 8, 2025 AITU
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Jan 22, 2025 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 22, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 22, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 22, 2025 REAP
USE AMENDMENT FILED
Jul 4, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Jul 4, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 7, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 12, 2024 NPUB
PUBLISHED FOR OPPOSITION
Mar 12, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 21, 2024 NONP
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 21, 2024 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 5, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 8, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 8, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 5, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 5, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 5, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 5, 2024 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 5, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 5, 2024 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 7, 2023 GNRN
NON-FINAL ACTION E-MAILED
Nov 7, 2023 GNRT
NON-FINAL ACTION WRITTEN
Nov 7, 2023 CNRT
ASSIGNED TO EXAMINER
Oct 28, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 18, 2023 NWOS
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Feb 3, 2023 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Feb 3, 2023 PARI
NEW APPLICATION ENTERED
Feb 3, 2023 NWAP